Advances in Therapy

, Volume 26, Issue 6, pp 613–626 | Cite as

Ramelteon: a review of its therapeutic potential in sleep disorders

  • Seithikurippu R. Pandi-Perumal
  • Venkatramanujam Srinivasan
  • D. Warren Spence
  • Adam Moscovitch
  • Rüdiger Hardeland
  • Gregory M. Brown
  • Daniel P. Cardinali
Open Access


Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon’s half-life is longer than that of melatonin, being metabolized in the body to four main metabolites, M-I, M-II, M-III, and M-IV. M-II has an affinity to MT1 and MT2 of about one-tenth of the parent compound, but its concentration in the circulation exceeds that of ramelteon by more than an order of magnitude. Ramelteon is effective in decreasing latency to persistent sleep and increasing total sleep time in freely moving monkeys. A number of clinical studies have been undertaken to study the efficacy of ramelteon in subjects with chronic insomnia. In almost all of these studies, ramelteon, in various doses of 4, 8, or 16 mg most commonly, significantly reduced sleep latency and increased sleep duration. Its primary action in sleep promotion is not a generalized gamma-aminobutyric (GABA)-ergic central nervous system depression, but rather it acts as a melatonergic agonist in the suprachiasmatic nucleus (and at other central nervous system sites), from where downstream processes, including GABA-ergic effects, are controlled via the hypothalamic sleep switch. Unlike other commonly prescribed hypnotic drugs, ramelteon is not associated with next morning hangover effects or reductions in alertness, nor has it been shown to cause withdrawal symptoms. The adverse symptoms reported with ramelteon are mild. All long-term investigations that have been carried out support the conclusion that ramelteon is a well tolerated and effective drug for the treatment of insomnia.


hypnotic insomnia melatonin ramelteon 


  1. 1.
    Dijk DJ, Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms. 1997;12:627–635.CrossRefPubMedGoogle Scholar
  2. 2.
    Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys. 2001;34:237–256.CrossRefPubMedGoogle Scholar
  3. 3.
    Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42:28–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27:119–130.CrossRefPubMedGoogle Scholar
  5. 5.
    Srinivasan V, Maestroni GJM, Cardinali DP, Esquifino AI, Perumal SR, Miller SC. Melatonin, immune function and aging. Immun Aging. 2005;2:17.CrossRefGoogle Scholar
  6. 6.
    Cardinali DP, Esquifino AI, Srinivasan V, et al. Melatonin and the immune system in aging. Neuroimmunomodulation. 2008;15:272–278.CrossRefPubMedGoogle Scholar
  7. 7.
    Reiter RJ. Pineal control of reproduction. Prog Clin Biol Res. 1981;59B:349–355.PubMedGoogle Scholar
  8. 8.
    Brzezinski A, Wurtman RJ. The pineal gland: its possible roles in human reproduction. Obstet Gynecol Surv. 1988;43:197–207.CrossRefPubMedGoogle Scholar
  9. 9.
    Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008;7:189–203.CrossRefPubMedGoogle Scholar
  10. 10.
    Cos S, Gonzalez A, Martinez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 2008;8:691–702.CrossRefPubMedGoogle Scholar
  11. 11.
    Bartness TJ, Goldman BD. Mammalian pineal melatonin: a clock for all seasons. Experientia. 1989;45:939–945.PubMedGoogle Scholar
  12. 12.
    Armstrong SM. Melatonin and circadian control in mammals. Experientia. 1989;45:932–938.PubMedGoogle Scholar
  13. 13.
    Chase JE, Gidal BE. Melatonin: therapeutic use in sleep disorders. Ann Pharmacother. 1997;31:1218–1226.PubMedGoogle Scholar
  14. 14.
    Cajochen C, Jewett ME, Dijk DJ. Human circadian melatonin rhythm phase delay during a fixed sleep-wake schedule interspersed with nights of sleep deprivation. J Pineal Res. 2003;35:149–157.CrossRefPubMedGoogle Scholar
  15. 15.
    Pandi-Perumal SR, Smits M, Spence W et al. Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Pandi-Perumal SR, Trakht I, Spence DW, Srinivasan V, Dagan Y, Cardinali DP. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol. 2008;4:436–447.CrossRefPubMedGoogle Scholar
  17. 17.
    Lieberman HR. Behavior, sleep and melatonin. J Neural Transm Suppl. 1986;21:233–241.PubMedGoogle Scholar
  18. 18.
    Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middleaged subjects. Psychopharmacology (Berl). 1996;126:179–181.CrossRefGoogle Scholar
  19. 19.
    Sack RL, Lewy AJ, Hughes RJ. Use of melatonin for sleep and circadian rhythm disorders. Ann Med. 1998;30:115–121.CrossRefPubMedGoogle Scholar
  20. 20.
    Vollrath L, Semm P, Gammel G. Sleep induction by intranasal administration of melatonin. Adv Biosci. 1981;29:327–329.Google Scholar
  21. 21.
    Buysse DJ, Germain A, Moul DE. Diagnosis, epidemiology and consequences of insomnia. Prim Psychiatry. 2005;12:37–44.Google Scholar
  22. 22.
    Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18:425–432.PubMedGoogle Scholar
  23. 23.
    Ancoli-Israel S, Cooke JR. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc. 2005;53:S264–S271.CrossRefPubMedGoogle Scholar
  24. 24.
    Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev. 2004;8:19–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Foley D, Ancoli-Israel S, Britz P, Walsh J. Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res. 2004;56:497–502.CrossRefPubMedGoogle Scholar
  26. 26.
    Engle-Friedman M, Bootzin RR, Hazlewood L, Tsao C. An evaluation of behavioral treatments for insomnia in the older adult. J Clin Psychol. 1992;48:77–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Silber MH. Clinical practice. Chronic insomnia. N Engl J Med. 2005;353:803–810.CrossRefPubMedGoogle Scholar
  28. 28.
    Kirkwood CK. Management of insomnia. J Am Pharm Assoc (Wash). 1999;39:688–696.Google Scholar
  29. 29.
    O’Hanlon J. Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. Primary Care Companion. J Clin Psychiatry. 2002;4:38–44.Google Scholar
  30. 30.
    Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469–476.PubMedCrossRefGoogle Scholar
  31. 31.
    Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116:91–95.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995;57:552–558.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19:423–431.PubMedGoogle Scholar
  34. 34.
    Gorfine T, Assaf Y, Goshen-Gottstein Y, Yeshurun Y, Zisapel N. Sleep-anticipating effects of melatonin in the human brain. Neuroimage. 2006;31:410–418.CrossRefPubMedGoogle Scholar
  35. 35.
    MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry. 1991;30:371–376.CrossRefPubMedGoogle Scholar
  36. 36.
    James SP, Sack DA, Rosenthal NE, Mendelson WB. Mela-tonin administration in insomnia. Neuropsycho-pharmacology. 1990;3:19–23.Google Scholar
  37. 37.
    Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res. 1996;5:61–65.CrossRefPubMedGoogle Scholar
  38. 38.
    Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18:598–603.PubMedGoogle Scholar
  39. 39.
    Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet. 1995;346:541–544.CrossRefPubMedGoogle Scholar
  40. 40.
    Nagtegaal JE, Kerkhof GA, Smits MG, Swart AC, Van Der Meer YG. Delayed sleep phase syndrome: a placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. J Sleep Res. 1998;7:135–143.CrossRefPubMedGoogle Scholar
  41. 41.
    Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med. 2001;63:40–48.PubMedGoogle Scholar
  42. 42.
    Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50.CrossRefPubMedGoogle Scholar
  43. 43.
    von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309:151–162.CrossRefGoogle Scholar
  44. 44.
    Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 2003;8:d1093–d1108.CrossRefPubMedGoogle Scholar
  45. 45.
    Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85:335–353.CrossRefPubMedGoogle Scholar
  46. 46.
    McArthur AJ, Hunt AE, Gillette MU. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: activation of protein kinase C at dusk and dawn. Endocrinology. 1997;138:627–634.CrossRefPubMedGoogle Scholar
  47. 47.
    Hunt AE, Al Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol. 2001;280:C110–C118.PubMedGoogle Scholar
  48. 48.
    Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102.CrossRefPubMedGoogle Scholar
  49. 49.
    Jin X, von Gall C, Pieschl RL, et al. Targeted disruption of the mouse Mel1b melatonin receptor. Mol Cell Biol. 2003;23:1054–1060.CrossRefPubMedGoogle Scholar
  50. 50.
    Edgar DM, Dement WC, Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci. 1993;13:1065–1079.PubMedGoogle Scholar
  51. 51.
    Krauchi K, Wirz-Justice A. Circadian clues to sleep onset mechanisms. Neuropsychopharmacology. 2001;25:S92–S96.CrossRefPubMedGoogle Scholar
  52. 52.
    Stone BM, Turner C, Mills SL, Nicholson AN. Hypnotic activity of melatonin. Sleep. 2000;23:663–669.PubMedGoogle Scholar
  53. 53.
    Skinner DC, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology. 1999;140:4399–4405.CrossRefPubMedGoogle Scholar
  54. 54.
    Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. 2004;5:523–532.CrossRefPubMedGoogle Scholar
  55. 55.
    Mendelson WB. A critical evaluation of the hypnotic efficacy of melatonin. Sleep. 1997;20:916–919.PubMedGoogle Scholar
  56. 56.
    Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301–310.CrossRefPubMedGoogle Scholar
  57. 57.
    Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009;15:32–51.CrossRefPubMedGoogle Scholar
  58. 58.
    Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58:1–10.PubMedGoogle Scholar
  59. 59.
    Stevenson S, Bryson S, Amayke D, Hibberd M. Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects. Clin Pharmacol Ther. 2004;75:P22.Google Scholar
  60. 60.
    Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007;47:485–496.CrossRefPubMedGoogle Scholar
  61. 61.
    Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Yoshikubo S, Miyamoto M. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res. 2004;1027:59–66.CrossRefPubMedGoogle Scholar
  62. 62.
    France CP, Weltman RH, Koek W, Cruz CM, McMahon LR. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies. Behav Neurosci. 2006;120:535–541.CrossRefPubMedGoogle Scholar
  63. 63.
    Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17–24.CrossRefPubMedGoogle Scholar
  64. 64.
    Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7:312–318.CrossRefPubMedGoogle Scholar
  65. 65.
    Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23:1005–1014.CrossRefPubMedGoogle Scholar
  66. 66.
    Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3:495–504.PubMedGoogle Scholar
  67. 67.
    Zammit G, Schwartz H, Roth T, Wang-Weigand S, Sainati S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med. 2009;10:55–59.CrossRefPubMedGoogle Scholar
  68. 68.
    Mini L, Wang-Weigand S, Zhang J. Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect. Clin Ther. 2008;30:1316–1323.CrossRefPubMedGoogle Scholar
  69. 69.
    Simpson D, Curran MP. Ramelteon: a review of its use in insomnia. Drugs. 2008;68:1901–1919.CrossRefPubMedGoogle Scholar
  70. 70.
    Wang-Weigand S, McCue M, Ogrinc F, Mini L. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. Curr Med Res Opin. 2009;25:1209–1213.CrossRefPubMedGoogle Scholar
  71. 71.
    Gross PK, Nourse R, Wasser TE. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med. 2009;5:28–33.PubMedGoogle Scholar
  72. 72.
    Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administra tion in adults with chronic primary insomnia. Sleep. 2009;32:351–360.PubMedGoogle Scholar
  73. 73.
    Dobkin RD, Menza M, Bienfait KL, Allen LA, Marin H, Gara MA. Ramelteon for the treatment of insomnia in menopausal women. Menopause Int. 2009;15:13–18.CrossRefPubMedGoogle Scholar
  74. 74.
    Regestein QR, Monk TH. Delayed sleep phase syndrome: a review of its clinical aspects. Am J Psychiatry. 1995;152:602–608.PubMedGoogle Scholar
  75. 75.
    Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase syndrome response to melatonin. Lancet. 1991;337:1121–1124.CrossRefPubMedGoogle Scholar
  76. 76.
    Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med. 2008;4:456–461.PubMedGoogle Scholar
  77. 77.
    Richardson G, Wang-Weigand S. Effects of longterm exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol. 2009;24:103–111.CrossRefPubMedGoogle Scholar
  78. 78.
    Zammit G, Wang-Weigand S, Rosenthal M, Peng X. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med. 2009;5:34–40.PubMedGoogle Scholar
  79. 79.
    Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry. 2009;70:467–476.CrossRefPubMedGoogle Scholar
  80. 80.
    Srinivasan V, Pandi-Perumal SR, Trahkt I et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci. 2009;119:821–846.CrossRefPubMedGoogle Scholar
  81. 81.
    Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath. 2007;11:159–164.CrossRefPubMedGoogle Scholar
  82. 82.
    Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437:1257–1263.CrossRefPubMedGoogle Scholar
  83. 83.
    Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J Biol Rhythms. 2006;21:482–493.CrossRefPubMedGoogle Scholar
  84. 84.
    Wurtman R. Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev Neurother. 2006;6:957–964.CrossRefPubMedGoogle Scholar
  85. 85.
    Gerdin MJ, Masana MI, Ren D, Miller RJ, Dubocovich ML. Short-term exposure to melatonin differentially affects the functional sensitivity and trafficking of the hMT1 and hMT2 melatonin receptors. J Pharmacol Exp Ther. 2003;304:931–939.CrossRefPubMedGoogle Scholar
  86. 86.
    Gerdin MJ, Masana MI, Rivera-Bermudez MA, et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J. 2004;18:1646–1656.CrossRefPubMedGoogle Scholar
  87. 87.
    Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther. 2006;28:1540–1555.CrossRefPubMedGoogle Scholar
  88. 88.
    Bellon A. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? J Psychiatr Pract. 2006;12:229–243.CrossRefPubMedGoogle Scholar
  89. 89.
    Cardinali DP, Golombek DA. Let there be sleep-on time. Lancet. 2009;373:439–441.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare Communications 2009

Authors and Affiliations

  • Seithikurippu R. Pandi-Perumal
    • 1
  • Venkatramanujam Srinivasan
    • 2
  • D. Warren Spence
    • 3
  • Adam Moscovitch
    • 4
  • Rüdiger Hardeland
    • 5
  • Gregory M. Brown
    • 6
  • Daniel P. Cardinali
    • 7
  1. 1.Somnogen IncNew YorkUSA
  2. 2.Sri Sathya Sai Medical, Educational and Research FoundationKovai Thirunagar CoimbatoreIndia
  3. 3.Sleep and Alertness ClinicTorontoCanada
  4. 4.Canadian Sleep Institute and CSI Research CenterTorontoCanada
  5. 5.Institute of Zoology and AnthropologyUniversity of GoettingenGoettingenGermany
  6. 6.Department of Psychiatry, Faculty of MedicineUniversity of TorontoOakvilleCanada
  7. 7.Departamento de Docencia e Investigación, Facultad de Ciencias MédicasPontificia Universidad Católica ArgentinaBuenos AiresArgentina

Personalised recommendations